3.4 C
New York
Tuesday, January 31, 2023

Is Bausch Health Companies Inc. (NYSE: BHC) Still On The Rise?

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Bausch Health Companies Inc. (BHC) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.06, or -0.84%, to $7.10. The Bausch Health Companies Inc. has recorded 39,189 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

This NYSE-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $7.16 and fluctuated between $7.22 as its day high and $6.71 as its day low. The current market capitalization of Bausch Health Companies Inc. is $2.60B. A total of 4.43 million shares were traded on the day, compared to an average of 5.01M shares.

In the most recent transaction, Bausch Health Companies Inc. sold 4,550,357 shares of BHC for 17.05 per share on Jun 01. After the transaction, the 10% Owner now owns 310,449,643 company shares. In a previous transaction on May 10, Bausch Health Companies Inc. sold 35,000,000 shares at 17.05 per share. BHC shares that 10% Owner owns now total 315,000,000.

Among the insiders who sold shares, Spurr Robert disposed of 1,595 shares on Apr 14 at a per-share price of $22.19. This resulted in the U.S. President-Pharma Business holding 90,506 shares of BHC after the transaction. In another insider transaction, Spurr Robert sold 4,846 shares at $22.20 per share on Mar 15. Company shares held by the U.S. President-Pharma Business now total 92,101.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BHC in the last 3 months, the mean price target is $12.00 with high estimates of $35.00 and low estimates of $6.00. In terms of 52-week highs and lows, BHC has a high of $28.08 and a low of $4.00.

As of this writing, BHC has an earnings estimate of $1.26 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of $1.5 per share and a lower estimate of $0.98. The company reported an EPS of $1.01 in the last quarter, which was -28.90% lower than expectations of $1.42.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BHC is Hold with a score of 3.38. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 7 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles